FDA Takes Steps to Limit Harm on Sudden Discontinuation of Prescription Opioids
Waismann Method® Applauds FDA’s Opioid Label Changes but Cautions New Guidelines Are Not Enough BEVERLY HILLS, Calif., April 10, 2019 — The U.S. Food and Drug Administration’s recent efforts to stem the tide of the opioid epidemic have received backlash from pain management doctors and chronic pain patients. By curtailing access to prescription opioids for…